Oragenics Inc. (OGEN)

Price$0.61

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-49.03%

Price vs S&P 500 (4W)-9.48%

VGM Score26.37

Market Capitalization$2.73M

All Metrics

Book Value / Share (Quarterly)$1.41

P/TBV (Annual)0.71x

Cash Flow / Share (Quarterly)$-2.13

Price vs S&P 500 (YTD)-33.50%

Gross Margin (TTM)61.29%

Net Profit Margin (TTM)-19750.00%

EPS (TTM)$-5.61

10-Day Avg Trading Volume0.06M

EPS Excl Extra (TTM)$-5.61

EPS (Annual)$-4.56

ROI (Annual)-115.67%

Gross Margin (Annual)60.64%

Net Profit Margin (5Y Avg)-17097.31%

Cash / Share (Quarterly)$1.40

ROA (Last FY)-97.76%

EBITD / Share (TTM)$-3.37

ROE (5Y Avg)-219.39%

Operating Margin (TTM)-20250.00%

Cash Flow / Share (Annual)$-2.16

P/B Ratio0.44x

P/B Ratio (Quarterly)0.39x

Net Income / Employee (Annual)$-3,280,800

EV / Revenue (TTM)-83.03x

Net Interest Coverage (TTM)-15.18x

ROA (TTM)-91.83%

EPS Incl Extra (Annual)$-4.56

Current Ratio (Annual)5.64x

Quick Ratio (Quarterly)4.67x

3-Month Avg Trading Volume0.20M

52-Week Price Return-87.82%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.53

P/S Ratio (Annual)72.50x

Asset Turnover (Annual)0.01x

52-Week High$9.60

Operating Margin (5Y Avg)-17266.36%

EPS Excl Extra (Annual)$-4.56

Tangible BV CAGR (5Y)15.55%

26-Week Price Return-35.44%

Quick Ratio (Annual)4.73x

13-Week Price Return-26.66%

Total Debt / Equity (Annual)0.03x

Current Ratio (Quarterly)5.73x

Enterprise Value$-3.32M

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-38.69%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)0.00x

Pretax Margin (Annual)-54862.52%

Cash / Share (Annual)$1.97

3-Month Return Std Dev73.69%

Gross Margin (5Y Avg)48.54%

Net Income / Employee (TTM)$-2,541,800

ROE (Last FY)-118.85%

Net Interest Coverage (Annual)-7.12x

EPS Basic Excl Extra (Annual)$-4.56

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.01x

EPS Incl Extra (TTM)$-5.61

Receivables Turnover (Annual)0.00x

ROI (TTM)-57.15%

P/S Ratio (TTM)68.24x

Pretax Margin (5Y Avg)-17097.31%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$6.43

Price vs S&P 500 (52W)-115.98%

Year-to-Date Return-22.11%

5-Day Price Return3.57%

EPS Normalized (Annual)$-4.56

ROA (5Y Avg)-276.76%

Net Profit Margin (Annual)-54862.52%

Month-to-Date Return0.69%

Cash Flow / Share (TTM)$-4.69

EBITD / Share (Annual)$-4.34

Operating Margin (Annual)-55524.33%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-206.03%

LT Debt / Equity (Quarterly)2.38x

EPS Basic Excl Extra (TTM)$-5.61

P/TBV (Quarterly)1.42x

P/B Ratio (Annual)0.39x

Inventory Turnover (TTM)0.00x

Pretax Margin (TTM)-19750.00%

Book Value / Share (Annual)$1.94

Price vs S&P 500 (13W)-37.32%

Beta1.26x

P/FCF (Annual)22.75x

Revenue / Share (TTM)$0.00

ROE (TTM)-59.11%

52-Week Low$0.50

mGradeD

vgmGradeD

Show chart for

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.14

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
OGENOragenics Inc.	—	—	D	$0.61
LLYEli Lilly & Co.	D	B	B	$1078.78
JNJJohnson & Johnson	C	C	C	$223.24
ABBVABBVIE INC.	D	C	C	$217.13
MRKMerck & Co., Inc.	C	C	C	$114.70
AZNAstraZeneca PLC	D	B	C	$176.28
NVSNovartis AG	C	C	C	$143.66
NVONovo-Nordisk A/S	B	B	B	$42.00
ABTAbbott Laboratories	C	C	D	$86.99
PFEPfizer Inc.	B	C	C	$25.34
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$32.83

About

Oragenics Inc develops nasal-delivery pharmaceutical treatments for neurology and infectious diseases. The company's lead candidate, ONP-002, is a synthetic neurosteroid designed to cross the blood-brain barrier and rapidly reduce inflammation, swelling, and oxidative stress. ONP-002 is being developed to treat concussions by restoring proper blood flow.